Enal Drugs Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 7.27 Cr
as on 16-11-2024
- Company Age 34 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.55 M
as on 16-11-2024
- Satisfied Charges ₹ 39.80 Cr
as on 16-11-2024
- Revenue 7.92%
(FY 2023)
- Profit -78.85%
(FY 2023)
- Ebitda 18.16%
(FY 2023)
- Net Worth 1.13%
(FY 2023)
- Total Assets 5.91%
(FY 2023)
About Enal Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 7.27 Cr.
The company currently has active open charges totaling ₹0.55 M. The company has closed loans amounting to ₹39.80 Cr, as per Ministry of Corporate Affairs (MCA) records.
Uma Sunkaraneni, Nikhil Mandha, Suresh Sunkaraneni, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230TG1990PTC011422
- Company No.
011422
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jun 1990
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Enal Drugs Pvt Ltd. offer?
Enal Drugs Pvt Ltd. offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API.
Who are the key members and board of directors at Enal Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Sunkaraneni  | Managing Director | 27-Jun-1990 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Uma Sunkaraneni | Director | 07-Nov-1994 | Current |
| Nikhil Mandha | Director | 16-Feb-2024 | Current |
| Achyuth Manne | Director | 16-Feb-2024 | Current |
Financial Performance and Corporate Structure Insights of Enal Drugs.
Enal Drugs Pvt Ltd., for the financial year ended 2023, experienced modest growth in revenue, with a 7.92% increase. The company also saw a substantial fall in profitability, with a 78.85% decrease in profit. The company's net worth moved up by a moderate rise of 1.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Enal Drugs?
In 2023, Enal Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Apichem Laboratories Private LimitedActive 4 years 11 monthsNikhil Mandha and Achyuth Manne are mutual person
- Apiform Laboratories Private LimitedActive 4 years 11 months
Nikhil Mandha and Achyuth Manne are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Hsbc Ltd Creation Date: 24 Feb 2000 | ₹0.55 M | Open |
Others Creation Date: 03 Jan 2023 | ₹1.04 Cr | Satisfied |
Hdfc Bank Limited Creation Date: 01 Sep 2022 | ₹3.41 M | Satisfied |
How Many Employees Work at Enal Drugs?
Enal Drugs has a workforce of 132 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Enal Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enal Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
